The pan-inhibitor of aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 1027-1062

  Li, Jin Ping ^a,b   Yang, Yin Xue ^a   Liu, Qi Lun ^a   Zhou, Zhi Wei ^b,c   Pan, Shu Ting ^b,d   He, Zhi Xu ^c   Zhang, Xueji ^e   Yang, Tianxin ^f   Pan, Si Yuan ^g   Duan, Wei ^h   He, Shu Ming ⁱ   Chen, Xiao Wu ^j   Qiu, Jia Xuan ^d   Zhou, Shu Feng ^b,c  

^a NINGXIA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c GUIZHOU MEDICAL UNIVERSITY   (China)

^d NANCHANG UNIVERSITY   (China)

^e UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^h DEAKIN UNIVERSITY   (Australia)

ⁱ SOUTHERN MEDICAL UNIVERSITY   (China)

^j SHUNDE HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

more..

Author keywords

Apoptosis; Autophagy; Breast cancer; Cell cycle; Danusertib; EMT

Indexed keywords

CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DANUSERTIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; SMALL INTERFERING RNA; AURORA KINASE; BENZAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC50; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; UPREGULATION; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL CYCLE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

APOPTOSIS; AURORA KINASES; AUTOPHAGY; BENZAMIDES; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MCF-7 CELLS; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84923144570     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S74412     Document Type: Article

References (60)

1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012;13(8):790–801.
2. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Can­cer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: IARC; 2013.
3. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
4. USCSW Group. United States Cancer Statistics: 1999–2011. Incidence and Mortality Web-based Report. Atlanta GA: Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2014.
5. Morgan G, Ward R, Barton M. The contribution of cytotoxic chemo­therapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol). 2004;16(8):549–560.
6. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 2004;4(8):592–603.
7. Andrews PD, Knatko E, Moore WJ, Swedlow JR. Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol. 2003;15(6):672683.
8. Kaestner P, Stolz A, Bastians H. Determinants for the efficiency of anti­cancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther. 2009;8(7):2046–2056.
9. Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237 – investigational Aurora A kinase inhibitor–in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2014;32(3):489–499.
10. Sehdev V, Katsha A, Ecsedy J, Zaika A, Belkhiri A, El-Rifai W. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas. Cancer. 2013;119(4):904–914.
11. Weier HU, Mao JH. Meta-analysis of Aurora Kinase A (AURKA) expression data reveals a significant correlation between increased AURKA expression and distant metastases in human ER-positive breast cancers. J Data Mining Genomics Proteomics. 2013;4(1):127.
12. Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013;19(7):1717–1728.
13. Ruchaud S, Carmena M, Earnshaw WC. The chromosomal passenger complex: one for all and all for one. Cell. 2007;131(2):230–231.
14. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8(7):547–566.
15. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer. 2010;10(12):825–841.
16. Lok W, Klein RQ, Saif MW. Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs. 2010;21(4):339–350.
17. Portella G, Passaro C, Chieffi P. Aurora B: a new prognostic marker and therapeutic target in cancer. Curr Med Chem. 2011;18(4):482–496.
18. Carpinelli P, Ceruti R, Giorgini ML, et al. PHA-739358, a potent inhibi­tor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther. 2007;6(12 Pt 1):3158–3168.
19. Meulenbeld HJ, Mathijssen RH, Verweij J, de Wit R, de Jonge MJ. Danusertib, an aurora kinase inhibitor. Expert Opin Investig Drugs. 2012;21(3):383–393.
20. Steeghs N, Eskens FA, Gelderblom H, et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol. 2009;27(30):5094–6101.
21. Li YC, He SM, He ZX, et al. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Lett. 2014;344(2):239–259.
22. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011;18(4):571–580.
23. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after pro­cessing. EMBO J. 2000;19(21):5720–5728.
24. Foroni C, Broggini M, Generali D, Damia G. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev. 2012;38(6):689–697.
25. Adhikary A, Chakraborty S, Mazumdar M, et al. Inhibition of epithelial to mesenchymal transition by E-cadherin up-regulation via repression of slug transcription and inhibition of E-cadherin degrada­tion: dual role of SMAR1 in breast cancer cells. J Biol Chem. 2014;289(37):25431–25444.
26. Dubois-Marshall S, Thomas JS, Faratian D, Harrison DJ, Katz E. Two possible mechanisms of epithelial to mesenchymal transition in invasive ductal breast cancer. Clin Exp Metastasis. 2011;28(8):811–818.
27. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res. 2007;5(1):1–10.
28. Ducat D, Zheng Y. Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res. 2004;301(1):60–67.
29. Gautschi OI, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008;14(6):1639–1648.
30. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 2003;22(4):451–464.
31. Li R, Yerganian G, Duesberg P, et al. Aneuploidy correlated 100% with chemical transformation of Chinese hamster cells. Proc Natl Acad Sci U S A. 1997;94(26):14506–14511.
32. Bayliss R, Sardon T, Vernos I, Conti E. Structural basis of Aurora-A acti­vation by TPX2 at the mitotic spindle. Mol Cell. 2003;12(4):851–862.
33. Crosio C, Fimia GM, Loury R, et al. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol. 2002;22(3):874–885.
34. Benten D, Keller G, Quaas A, et al. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia. 2009;11(9):934–944.
35. Xie LI, Kassner M, Munoz RM, et al. Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochem Pharmacol. 2012;83(4):452–461.
36. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407(6805):770–776.
37. Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K, Linn S. Molecu­lar mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39–85.
38. Galluzzi L, Bravo-San Pedro JM, Vitale I, et al. Essential versus acces­sory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ. 2015;22(1):58–73.
39. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol. 1980;68:251–306.
40. Wolf BB, Green DR. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem. 1999;274(29):20049–20052.
41. McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 2013;5(4):a008656.
42. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9(3):231–241.
43. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290(5497):1717–1721.
44. Denton D, Nicolson S, Kumar S. Cell death by autophagy: facts and apparent artefacts. Cell Death Differ. 2012;19(1):87–95.
45. Yang S Kimmelman. A critical role for autophagy in pancreatic cancer. Autophagy. 2011;7(8):912–913.
46. Gajewska M, Sobolewska A, Kozlowski M, Motyl T. Role of autophagy in mammary gland development. J Physiol Pharmacol. 2008;59(Suppl 9):237–249.
47. Cook KL, Shajahan AN, Clarke R. Autophagy and endocrine resistance in breast cancer. Expert Rev Anticancer Ther. 2011;11(8):1283–1294.
48. Chen N, Karantza-Wadsworth V. Role and regulation of autophagy in cancer. Biochim Biophys Acta. 2009;1793(9):1516–1523.
49. Maycotte P, Thorburn A. Targeting autophagy in breast cancer. World J Clin Oncol. 2014;5(3):224–240.
50. Hsieh CC, Kuro-o M, Rosenblatt KP, Brobey R, Papaconstantinou J. The ASK1-Signalosome regulates p38 MAPK activity in response to levels of endogenous oxidative stress in the Klotho mouse models of aging. Aging (Albany NY). 2010;2(9):597–611.
51. Wang WI, Fan H, Zhou Y, Duan P, Zhao G, Wu G. Knockdown of autophagy-related gene BECLIN 1 promotes cell growth and inhibits apoptosis in the A549 human lung cancer cell line. Mol Med Rep. 2013;7(5):1501–1505.
52. Lee YJ, Ha YJ, Kang YN, et al. The autophagy-related marker LC3 can predict prognosis in human hepatocellular carcinoma. PLoS One. 2013;8(11):e81540.
53. Sui X, Kong N, Ye L, et al. p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett. 2014;344(2):174–179.
54. Dunlop EA, Tee AR. mTOR and autophagy: a dynamic relation­ship governed by nutrients and energy. Semin Cell Dev Biol. 2014;36C:121–129.
55. Brancho D, Tanaka N, Jaeschke A, et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 2003;17(16):1969–1978.
56. Brancho DI, Ventura JJ, Jaeschke A, Doran B, Flavell RA, Davis RJ. Role of MLK3 in the regulation of mitogen-activated protein kinase signaling cascades. Mol Cell Biol. 2005;25(9):3670–3681.
57. Comes F, Matrone A, Lastella P, et al. A novel cell type-specific role of p38α in the control of autophagy and cell death in colorectal cancer cells. Cell Death Differ. 2007;14(4):693–702.
58. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39(3):305–318.
59. Beavon IR. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer. 2000;36(13 Spec No):1607–1620.
60. Shin K, Margolis B. ZOning out tight junctions. Cell. 2006;126(4):647–649.